Related Experiment Video
Updated: Jun 10, 2025

A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model
Published on: September 11, 2020
Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers
Viktor Klementa1, Nadezda Petejova2,3,4, Pavel Horak1
1Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic.
Abstract:
Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.
Insights
Gentamicin antibiotic use can cause acute kidney injury (AKI). MicroRNAs (miRNAs) show altered expression in gentamicin nephrotoxicity, suggesting they could be early biomarkers for detecting and monitoring kidney damage.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Gentamicin, an aminoglycoside antibiotic, is vital for treating bacterial infections but poses a risk of nephrotoxicity, leading to acute kidney injury (AKI).
- Early and accurate diagnosis of gentamicin-induced AKI is critical for effective patient management.
- Non-protein-coding RNAs, particularly microRNAs (miRNAs), are emerging as potential biomarkers for kidney injury.
Purpose of the Study:
- To investigate the role of microRNAs (miRNAs) in gentamicin-induced nephrotoxicity.
- To explore the potential of miRNAs as sensitive biomarkers for early detection and monitoring of AKI in patients receiving gentamicin therapy.
Main Methods:
- Review of existing research on miRNAs implicated in gentamicin-induced nephrotoxicity.
- Analysis of miRNA expression changes in vitro, in vivo, and human clinical studies following gentamicin exposure.
- Correlation of miRNA dysregulation with the severity of kidney injury.
Main Results:
- Numerous miRNAs are involved in pathways critical to gentamicin-induced kidney injury, including inflammation, cell death, and oxidative stress.
- Changes in miRNA expression levels have been observed in response to gentamicin exposure across various models.
- The dysregulation of specific miRNAs correlates with the extent of kidney damage.
Conclusions:
- MicroRNAs (miRNAs) are significantly dysregulated in gentamicin-induced nephrotoxicity.
- These miRNAs hold promise as sensitive and reliable biomarkers for the early diagnosis and monitoring of acute kidney injury caused by gentamicin.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management

